Introduction
Materials and methods
Network pharmacology
Molecular docking
Cell cultures and treatment
Cell viability assay
Construction of PCOS models on mice
Western blot analysis
RNA extraction and RT-qPCR analysis
-
ACTB-Homo.
-
5′-CATGTACGTTGCTATCCAGGC-3′(Forward).
-
5′-CTCCTTAATGTCACGCACGAT-3′(Reverse).
-
ACTB-Mouse.
-
5′-GGCTGTATTCCCCTCCATCG-3′(Forward).
-
5′-CCAGTTGGTAACAATGCCATGT-3′(Reverse).
-
PRKCA-Homo.5′- ATGTCACAGTACGAGATGCAAAA-3′(Forward).5′- GCTTTCATTCTTGGGATCAGGAA-3′(Reverse).PRKCA -Mouse.5′- GTTTACCCGGCCAACGACT-3′(Forward).5′- GGGCGATGAATTTGTGGTCTT-3′(Reverse).
The detection of reactive oxygen species (ROS) for GCs
Statistical analyses
Results
Screening of the candidate genes of the active compounds in ASP
Molecule name | Mol ID | Oral Bioavailability (OB) % | Drug-like (DL) |
---|---|---|---|
Beta-sitosterol | MOL000358 | 36.91 | 0.75 |
Sitosterol | MOL000359 | 36.91 | 0.75 |
Methylprotodioscin_qt | MOL003889 | 35.12 | 0.86 |
Pseudoprotodioscin_qt | MOL003891 | 37.93 | 0.87 |
7-Methoxy-2-methyl isoflavone | MOL003896 | 42.56 | 0.20 |
Asparaside A_qt | MOL003901 | 30.60 | 0.86 |
Stigmasterol | MOL000449 | 43.83 | 0.76 |
Diosgenin | MOL000546 | 80.88 | 0.81 |
Quercetin | MOL000098 | 46.43 | 0.28 |
Screening of candidate targets for PCOS
Network pharmacology analysis of ASP in PCOS
Screening of hub genes for ASP targeting PCOS
Description | P value | Q value | Count |
---|---|---|---|
Chemical carcinogenesis receptor activation | 1.71E-17 | 2.02E-15 | 21 |
Proteoglycans in cancer | 8.34E-12 | 4.92E-10 | 16 |
Hepatocellular carcinoma | 8.29E-11 | 2.43E-09 | 14 |
Lipid and atherosclerosis | 2.03E-10 | 3.43E-09 | 15 |
Molecular docking simulates the binding of PRKCA with ASP active ingredients
Molecule name | Docking score (kcal/mol) | Protein |
---|---|---|
Beta-sitosterol | -5.21 | PRKCA |
Sitosterol | -5.47 | PRKCA |
Pseudoprotodioscin_qt | -5.91 | PRKCA |
7-Methoxy-2-methyl isoflavone | -4.96 | PRKCA |
Stigmasterol | -6.28 | PRKCA |
Diosgenin | -6.15 | PRKCA |
Quercetin | -4.77 | PRKCA |